RU2006140081A - Композиции и способы для регуляции развития сосудов - Google Patents
Композиции и способы для регуляции развития сосудов Download PDFInfo
- Publication number
- RU2006140081A RU2006140081A RU2006140081/13A RU2006140081A RU2006140081A RU 2006140081 A RU2006140081 A RU 2006140081A RU 2006140081/13 A RU2006140081/13 A RU 2006140081/13A RU 2006140081 A RU2006140081 A RU 2006140081A RU 2006140081 A RU2006140081 A RU 2006140081A
- Authority
- RU
- Russia
- Prior art keywords
- egfl7
- pathological condition
- antagonist
- individual
- agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 21
- 239000000203 mixture Substances 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 102100032031 Epidermal growth factor-like protein 7 Human genes 0.000 claims 10
- 101000921195 Homo sapiens Epidermal growth factor-like protein 7 Proteins 0.000 claims 10
- 239000005557 antagonist Substances 0.000 claims 9
- 230000001575 pathological effect Effects 0.000 claims 8
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 7
- 230000033115 angiogenesis Effects 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000010595 endothelial cell migration Effects 0.000 claims 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000010232 migration assay Methods 0.000 claims 1
- 210000003556 vascular endothelial cell Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (20)
1. Способ снижения или ингибирования ангиогенеза у индивидуума со связанным с ангиогенезом патологическим состоянием, предусматривающий введение индивидууму антагониста EGFL7, способного препятствовать индуцируемой EGFL7 миграции эндотелиальных клеток, тем самым снижая или ингибируя ангиогенез у индивидуума.
2. Способ по п.1, где антагонист EGFL7 представляет собой антитело к EGFL7.
3. Способ по п.1, где патологическое состояние представляет собой новообразование.
4. Способ по п. 3, где новообразование представляет собой карциному.
5. Способ по п.1, где патологическое состояние связано с глазом.
6. Способ по п.5, где патологическое состояние представляет собой внутриглазное неоваскулярное заболевание.
7. Способ по п.1, дополнительно предусматривающий введение индивидууму противоангиогенного средства.
8. Способ по п.7, где противоангиогенное средство вводят перед или после введения антагониста EGFL7.
9. Способ по п.7, где противоангиогенное средство вводят одновременно с антагонистом EGFL7.
10. Способ по п.7, где противоангиогенное средство представляет собой антагонист фактора роста клеток эндотелия сосудов (VEGF).
11. Способ по п.10, где антагонист VEGF представляет собой антитело к VEGF.
12. Способ по п.11, где антитело к VEGF представляет собой бевацизумаб.
13. Способ по п.1, где способность антагониста EGFL7 препятствовать индуцируемой EGFL7 миграции эндотелиальных клеток выявляют в анализе миграции клеток in vitro.
14. Способ повышения эффективности противоангиогенного средства у индивидуума со связанным с ангиогенезом патологическим состоянием, предусматривающий введение индивидууму антагониста EGFL7 в сочетании со способным ингибировать ангиогенез противоангиогенным средством, тем самым усиливая указанную ингибирующую активность противоангиогенного средства.
15. Способ по п.14, где антагонист EGFL7 представляет собой антитело к EGFL7.
16. Способ по п.14, где патологическое состояние представляет собой новообразование.
17. Способ по п.16, где новообразование представляет собой карциному.
18. Способ по п.14, где патологическое состояние связано с глазом.
19. Способ по п.18, где патологическое состояние представляет собой внутриглазное неоваскулярное заболевание.
20. Способ по п.17, дополнительно предусматривающий введение химиотерапевтического средства.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56205404P | 2004-04-14 | 2004-04-14 | |
| US60/562,054 | 2004-04-14 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009114508/15A Division RU2009114508A (ru) | 2004-04-14 | 2009-04-16 | Композиции и способы для регуляции развития сосудов |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006140081A true RU2006140081A (ru) | 2008-05-20 |
| RU2365382C2 RU2365382C2 (ru) | 2009-08-27 |
Family
ID=35355481
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006140081/13A RU2365382C2 (ru) | 2004-04-14 | 2005-04-14 | Композиции и способы для регуляции развития сосудов |
| RU2009114508/15A RU2009114508A (ru) | 2004-04-14 | 2009-04-16 | Композиции и способы для регуляции развития сосудов |
| RU2013146239/15A RU2013146239A (ru) | 2004-04-14 | 2013-10-16 | Композиции и способы для регуляции развития сосудов |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009114508/15A RU2009114508A (ru) | 2004-04-14 | 2009-04-16 | Композиции и способы для регуляции развития сосудов |
| RU2013146239/15A RU2013146239A (ru) | 2004-04-14 | 2013-10-16 | Композиции и способы для регуляции развития сосудов |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20070031437A1 (ru) |
| EP (1) | EP1734998A2 (ru) |
| JP (3) | JP5599136B2 (ru) |
| KR (1) | KR101227817B1 (ru) |
| CN (2) | CN1997394B (ru) |
| AU (1) | AU2005249377A1 (ru) |
| BR (1) | BRPI0509420A (ru) |
| CA (1) | CA2563445C (ru) |
| IL (2) | IL178329A0 (ru) |
| MX (1) | MXPA06011851A (ru) |
| NZ (1) | NZ550110A (ru) |
| RU (3) | RU2365382C2 (ru) |
| WO (1) | WO2005117968A2 (ru) |
| ZA (1) | ZA200608615B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2412251C1 (ru) * | 2009-06-15 | 2011-02-20 | Юрий Леонидович Дорохов | Антитело против фактора роста эндотелия сосудов и способ продукции антитела в растении |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0509420A (pt) | 2004-04-14 | 2007-09-04 | Genentech Inc | método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico |
| AR059851A1 (es) * | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
| JP5437797B2 (ja) | 2006-06-12 | 2014-03-12 | サイトス バイオテクノロジー アーゲー | Ｒｎａバクテリオファージのウイルス様粒子にオリゴヌクレオチドをパッケージ化するための方法 |
| WO2008010986A2 (en) * | 2006-07-17 | 2008-01-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of modulating angiogenesis |
| WO2008130719A1 (en) * | 2007-04-24 | 2008-10-30 | University Of Louisville | Therapeutic beta-glucan combinations |
| JP2009005584A (ja) * | 2007-06-26 | 2009-01-15 | Miyazaki Prefecture | ゲル化剤、凍結保存剤、細胞保存用容器、細胞の凍結保存方法、細胞の融解方法、哺乳動物の細胞 |
| US9549971B2 (en) * | 2008-01-14 | 2017-01-24 | Genentech, Inc. | Methods for inhibiting angiogenesis using EGFL8 antagonists |
| WO2010034155A1 (zh) * | 2008-09-25 | 2010-04-01 | 中南大学湘雅医院 | 一种通过检测样品中eglf7来诊断肝细胞癌的试剂盒 |
| BRPI1007706A2 (pt) * | 2009-05-08 | 2019-04-02 | Genentech, Inc. | anticorpo anti-egfl7, anticorpo biespecífico, ácido nucléico, vetor, célula hospedeira, composição, método para produzir um anticorpo anti-egfl7, método de redução ou inibição da angiogênese em um indivíduo, método de acentuação da eficácia de um agente antiangiogênese em um indivíduo e método de redução ou inibição da perfusão e permeabilidade de um tumor em um indivíduo |
| US20110076271A1 (en) * | 2009-07-13 | 2011-03-31 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| KR20190067275A (ko) * | 2009-12-21 | 2019-06-14 | 제넨테크, 인크. | 항체 제제 |
| WO2013061112A1 (en) | 2011-10-24 | 2013-05-02 | Centre National De La Recherche Scientifique | Use of egfl7 modulators for promoting or inhibiting migration of immune cells across vascular endothelium |
| WO2013142961A1 (en) * | 2012-03-27 | 2013-10-03 | London Health Sciences Centre Research Inc. | Egfl7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis |
| WO2015077643A2 (en) * | 2013-11-21 | 2015-05-28 | Mfr Products, Inc. | Therapeutic device to assist in myofascial release, and method of use |
| UA123763C2 (uk) * | 2014-10-23 | 2021-06-02 | Енджіем Байофармасьютикалз, Інк. | Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19 |
| CN105543183B (zh) * | 2016-01-08 | 2019-04-12 | 吴帆 | 人肝癌细胞Egfl8基因过表达慢病毒在制备治疗肝癌药物中的应用 |
| EP3615075A4 (en) | 2017-04-24 | 2021-01-20 | Ohio State Innovation Foundation | RECOMBINANT EGFL7, ANTI-EGFL7 ANTIBODIES, AND THEIR USES |
| RU2678200C1 (ru) * | 2018-07-27 | 2019-01-24 | Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" | Лекарственная пленка пролонгированного действия и способ её получения |
| WO2022025783A1 (ru) | 2020-07-28 | 2022-02-03 | Общество с ограниченной ответственностью "Ангиолайф" | Применения комбинации генов ангиогенных и нейротрофических факторов |
| CN114410642B (zh) * | 2021-12-31 | 2023-01-17 | 苏州大学 | 一种急性t淋巴细胞白血病药物靶点及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU597323B2 (en) * | 1985-11-22 | 1990-05-31 | Teijin Limited | Angiogenic factor derived from blood vessel endothelial cells |
| JPH01503705A (ja) | 1986-08-18 | 1989-12-14 | ビオタ・シャンティフィック・マネージメント・ピーティーワイ・リミテッド | 脈管形成の刺激および内皮化の増進 |
| RU2194528C2 (ru) * | 1996-05-31 | 2002-12-20 | Дзе Скриппс Рисерч Инститьют | Способы и композиции, используемые для ингибирования ангиогенеза |
| WO2002008284A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| WO2000053752A2 (en) | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030166907A1 (en) * | 1997-06-18 | 2003-09-04 | Zymogenetics, Inc. | Mammalian neuro-growth factor like protein |
| AU737132B2 (en) * | 1997-06-18 | 2001-08-09 | Zymogenetics Inc. | Mammalian neuro-growth factor like protein |
| US5972338A (en) | 1997-09-19 | 1999-10-26 | Genentech, Inc. | Tie ligands homologues |
| US20030166110A1 (en) | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7105640B2 (en) | 1997-10-17 | 2006-09-12 | Genentech, Inc. | Anti-pro792 antibodies |
| US20030199436A1 (en) | 1997-10-17 | 2003-10-23 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6974696B2 (en) | 1997-10-17 | 2005-12-13 | Genentech, Inc. | PRO853 nucleic acids |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| US20030069178A1 (en) | 1997-10-17 | 2003-04-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030039648A1 (en) | 1998-09-16 | 2003-02-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
| US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| ES2312205T3 (es) * | 1998-03-10 | 2009-02-16 | Genentech, Inc. | Nuevo polipeptido y acidos nucleicos que lo codifican. |
| US7371836B2 (en) | 1998-03-27 | 2008-05-13 | Genentech, Inc. | PRO526 nucleic acids |
| US7202338B2 (en) | 1998-03-31 | 2007-04-10 | Genentech, Inc. | PRO731 polypeptides |
| US7196176B2 (en) | 1998-04-01 | 2007-03-27 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6962797B2 (en) | 1998-04-15 | 2005-11-08 | Genentech, Inc. | Nucleic acids encoding PRO615 |
| DE19817946A1 (de) | 1998-04-17 | 1999-10-21 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe |
| AU3965799A (en) | 1998-04-23 | 1999-11-08 | Millennium Pharmaceuticals, Inc. | Novel molecules of the t125-related protein family and uses thereof |
| US7067636B2 (en) | 1998-05-06 | 2006-06-27 | Genentech, Inc. | Anti-pro 1017 antibodies |
| US20030186368A1 (en) | 1998-05-13 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
| US7019115B2 (en) | 1998-05-22 | 2006-03-28 | Genentech, Inc. | Pro1017 polypeptides |
| US7220835B2 (en) | 1998-07-30 | 2007-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1135494A2 (en) | 1998-12-11 | 2001-09-26 | Incyte Pharmaceuticals, Inc. | Neuron-associated proteins |
| US20030187196A1 (en) | 1998-12-30 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2383592A1 (en) | 1999-03-31 | 2000-10-05 | Curagen Corporation | 2384891 acids including open reading frames encoding polypeptides; orfx |
| WO2000063756A1 (en) | 1999-04-16 | 2000-10-26 | Fujikin Incorporated | Parallel bypass type fluid feeding device, and method and device for controlling fluid variable type pressure system flow rate used for the device |
| US7214656B2 (en) | 1999-04-28 | 2007-05-08 | Genentech, Inc. | PRO792 polypeptides |
| WO2001002563A2 (en) | 1999-07-02 | 2001-01-11 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| US7589172B2 (en) | 1999-07-20 | 2009-09-15 | Genentech, Inc. | PRO256 polypeptides |
| TWI265167B (en) | 1999-11-29 | 2006-11-01 | Akzo Nobel Nv | 3-methylene steroid derivatives |
| EP1285084A1 (en) | 2000-01-25 | 2003-02-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US7193050B2 (en) | 2000-02-18 | 2007-03-20 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2412211A1 (en) | 2000-06-23 | 2002-01-03 | Genetech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US7115415B2 (en) | 2000-09-15 | 2006-10-03 | Genentech, Inc. | PRO9821 nucleic acids |
| US7205392B2 (en) * | 2001-02-05 | 2007-04-17 | Innoventus Project Ab | Histidine-rich glycoprotein |
| US20030224984A1 (en) * | 2001-06-20 | 2003-12-04 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US20030100497A1 (en) | 2001-06-20 | 2003-05-29 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US20030023042A1 (en) | 2001-12-06 | 2003-01-30 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| FR2851249A1 (fr) * | 2003-02-17 | 2004-08-20 | Commissariat Energie Atomique | Nouveau facteur soluble secrete par les cellules endotheliales des vaisseaux sanguins, capable d'inhiber le recrutement des cellules perivasculaires du type musculaire lisse et ses applications |
| BRPI0509420A (pt) * | 2004-04-14 | 2007-09-04 | Genentech Inc | método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico |
-
2005
- 2005-04-14 BR BRPI0509420-8A patent/BRPI0509420A/pt not_active IP Right Cessation
- 2005-04-14 KR KR1020067021268A patent/KR101227817B1/ko not_active Expired - Fee Related
- 2005-04-14 MX MXPA06011851A patent/MXPA06011851A/es active IP Right Grant
- 2005-04-14 AU AU2005249377A patent/AU2005249377A1/en not_active Abandoned
- 2005-04-14 CN CN2005800195117A patent/CN1997394B/zh not_active Expired - Fee Related
- 2005-04-14 CA CA2563445A patent/CA2563445C/en not_active Expired - Fee Related
- 2005-04-14 ZA ZA200608615A patent/ZA200608615B/en unknown
- 2005-04-14 JP JP2007508646A patent/JP5599136B2/ja not_active Expired - Fee Related
- 2005-04-14 CN CN2012103813601A patent/CN102895663A/zh active Pending
- 2005-04-14 RU RU2006140081/13A patent/RU2365382C2/ru not_active IP Right Cessation
- 2005-04-14 EP EP05804788A patent/EP1734998A2/en not_active Ceased
- 2005-04-14 NZ NZ550110A patent/NZ550110A/en not_active IP Right Cessation
- 2005-04-14 WO PCT/US2005/013658 patent/WO2005117968A2/en not_active Ceased
-
2006
- 2006-09-27 IL IL178329A patent/IL178329A0/en active IP Right Grant
- 2006-10-12 US US11/546,760 patent/US20070031437A1/en not_active Abandoned
-
2009
- 2009-01-22 US US12/357,819 patent/US20090297512A1/en not_active Abandoned
- 2009-04-16 RU RU2009114508/15A patent/RU2009114508A/ru unknown
-
2010
- 2010-10-14 US US12/904,813 patent/US8790646B2/en not_active Expired - Fee Related
-
2011
- 2011-09-01 JP JP2011190733A patent/JP2011241230A/ja not_active Withdrawn
-
2013
- 2013-06-13 IL IL226899A patent/IL226899A0/en unknown
- 2013-09-24 JP JP2013196507A patent/JP2013256535A/ja not_active Withdrawn
- 2013-10-16 RU RU2013146239/15A patent/RU2013146239A/ru not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2412251C1 (ru) * | 2009-06-15 | 2011-02-20 | Юрий Леонидович Дорохов | Антитело против фактора роста эндотелия сосудов и способ продукции антитела в растении |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2365382C2 (ru) | 2009-08-27 |
| CN102895663A (zh) | 2013-01-30 |
| IL178329A0 (en) | 2007-02-11 |
| IL226899A0 (en) | 2013-07-31 |
| CN1997394B (zh) | 2012-11-28 |
| RU2009114508A (ru) | 2010-10-27 |
| US20090297512A1 (en) | 2009-12-03 |
| ZA200608615B (en) | 2008-05-28 |
| JP2007532685A (ja) | 2007-11-15 |
| US20120003208A1 (en) | 2012-01-05 |
| WO2005117968A2 (en) | 2005-12-15 |
| KR101227817B1 (ko) | 2013-01-29 |
| JP2013256535A (ja) | 2013-12-26 |
| JP2011241230A (ja) | 2011-12-01 |
| BRPI0509420A (pt) | 2007-09-04 |
| AU2005249377A1 (en) | 2005-12-15 |
| NZ550110A (en) | 2009-09-25 |
| JP5599136B2 (ja) | 2014-10-01 |
| WO2005117968A3 (en) | 2006-06-08 |
| CA2563445A1 (en) | 2005-12-15 |
| CA2563445C (en) | 2016-07-19 |
| RU2013146239A (ru) | 2015-04-27 |
| EP1734998A2 (en) | 2006-12-27 |
| US20070031437A1 (en) | 2007-02-08 |
| US8790646B2 (en) | 2014-07-29 |
| KR20070029687A (ko) | 2007-03-14 |
| MXPA06011851A (es) | 2006-12-14 |
| CN1997394A (zh) | 2007-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006140081A (ru) | Композиции и способы для регуляции развития сосудов | |
| Gentilini et al. | Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial | |
| Leyvraz et al. | Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial | |
| Dubuisson et al. | Inhibition of rat liver fibrogenesis through noradrenergic antagonism | |
| Dib et al. | Role of mast cells in the development of pancreatitis‐induced multiple organ dysfunction | |
| Atucha et al. | Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis | |
| JP2007532685A5 (ru) | ||
| Solà et al. | Challenges and management of liver cirrhosis: pathophysiology of renal dysfunction in cirrhosis | |
| RU2010133957A (ru) | Способы ингибирования ангиогенеза с помощью антагонистов egfl8 | |
| RU2009128245A (ru) | Применение гена сывороточного амилоида а для диагностики и лечения глаукомы и идентификации антиглаукомных агентов | |
| AU2008305407B2 (en) | Pharmacological adjunctive treatment associated with glaucoma filtration surgery | |
| Garini et al. | Interferon-α in combination with ribavirin as initial treatment for hepatitis C virus–associated cryoglobulinemic membranoproliferative glomerulonephritis | |
| Leithead et al. | advances in the management of patients with cirrhosis and portal hypertension‐related renal dysfunction | |
| Yan et al. | Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation | |
| Ward et al. | Drug therapies to delay the progression of chronic kidney disease | |
| Angus | Role of endothelin in systemic and portal resistance in cirrhosis | |
| Israni et al. | Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients | |
| Bakris | Diabetic nephropathy: What you need to know to preserve kidney function | |
| Liu et al. | Effect of vascular bradykinin on pancreatic microcirculation and hemorheology in rats with severe acute pancreatitis | |
| Vierhapper et al. | Effect of endothelin‐1 in man: pretreatment with nifedipine, with indomethacin and with cyclosporine A | |
| Rusai et al. | Renin inhibition mitigates anti-angiogenesis in spontaneously hypertensive rats | |
| JP2022512822A (ja) | 腫瘍を治療するための薬物の調製におけるファミチニブと組み合わせた抗ｐｄ－１抗体の使用 | |
| Futrakul et al. | Renal perfusion and nephronal structure | |
| Poole et al. | Glomerular disease in cirrhosis | |
| RU2006146976A (ru) | Способ профилактики формирования и прогрессирования дистрофии сетчатки у беременных с миопией и гестозом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20210415 |